This is my second time trying GLP-1s, and it's been an awesome and smooth ride
Direct answer: Clinicians compare the medication timeline with symptoms, rule out other causes, and may reassess symptoms after changing the treatment plan
Opportunity Pathways - GLP-1 Diabetes Treatment Drugs Market The GLP-1 diabetes treatment drugs market represents one of the most explosive pharmaceutical opportunities of the decade, with the market projected to surge from USD 6,556.5 million in 2025 to USD 62,543.2 million by 2035 at an extraordinary 25.3% CAGRa 9.5X expansion driven by the global diabetes epidemic, breakthrough efficacy data, and expanding therapeutic applications beyond glucose control to include weight management and cardiovascular protection
While medications provide a concentrated, synthetic version of the hormone, your body naturally secretes GLP-1 in the L-cells of the gut in response to specific nutrients
In November 2023, AstraZeneca made a potential $2 billion investment in the expanding anti-obesity medical industry by licensing an experimental pill from China's Eccogene ECC5004, which is part of a class of extremely efficient weight-loss medicines known as GLP-1 receptor agonists in current injectable therapies
